Medivir Announces Positive Phase 2b 48-week (SVR24) Interim Results of TMC435 in Treatment-Naïve Patients Chronically Infected with Genotype-1 Hepatitis C Virus
Medivir AB announced further positive results from the phase 2b PILLAR (C205) study of TMC435 in treatment-naïve patients with hepatitis C virus (HCV) genotype-1:
- TMC435 was safe and well tolerated with no clinically relevant differences in adverse events between treatment groups and standard of care (SoC).
- In the TMC435 treatment groups 83% of patients were able to stop all therapy at week 24
- Potent and consistent antiviral efficacy was demonstrated with SVR24 rates of up to 84%
"We are very pleased by both the efficacy and safety shown by TMC435 in this 48-Week interim analysis. With the additional features of once daily dosing, TMC435 also has a more convenient and competitive dosing regimen” stated Bertil Samuelsson, CSO of Medivir. "The recently published start of three global phase 3 clinical trials is an important milestone in the continued development of TMC435. We are now looking forward to the 48-week interim data from the phase 2b trial C206 (ASPIRE) in treatment-experienced patients during Q2 2011.”
The 48-week interim results from the 5-arm phase 2b response guided PILLAR study in 386 treatment-naïve patients showed further consistent high antiviral activity, and the good safety and tolerability previously demonstrated was confirmed. The 24-week (EOT) interim results were presented at the AASLD conference in Boston, MA, in November 2010.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
